Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution
David A. Kennedy
TL;DR
Using monoclonal antibodies to treat measles could cause the virus to evolve in ways that weaken vaccine effectiveness.
Contribution
The paper highlights the risk of monoclonal antibody therapies promoting adverse evolution in the measles virus.
Findings
Monoclonal antibody therapies may drive measles virus evolution.
Such evolution could undermine the protection provided by vaccination.
Abstract
Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. These therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination, outweighing potential benefits. Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. This Perspective argues that such therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsVirology and Viral Diseases · Monoclonal and Polyclonal Antibodies Research · vaccines and immunoinformatics approaches